LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia.

Tiangen Wu,Xi Chen,Kequan Xu,Caixia Dai,Xiaomian Li,Yang-Wen-Qing Zhang,Jinghua Li,Meng Gao,Yingyi Liu,Fusheng Liu,Xutao Zhang,Bicheng Wang,Peng Xia,Zhen Li,Weijie Ma,Yufeng Yuan

Hepatology (Baltimore, Md.)（2023）

引用 0|浏览17

暂无评分

摘要

These findings provide proof-of-concept evidence supporting LMO7 as a robust suppressor of NASH in the context of hyperlipidemia, indicating that targeting the LMO7-TRIM47 axis is a promising therapeutic strategy for NASH.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要